143 related articles for article (PubMed ID: 2977221)
21. Interferon alpha-2 for hairy cell leukemia: evidence for induction of RNA synthesis in hairy cells and failure to correlate enhancement of natural killer cells with elimination of hairy cells.
Schwarzmeier JD; Schwabe M; Prischl F; Wagner L; Lion T; Micksche M; Köller U
Eur J Haematol; 1987 Nov; 39(5):418-25. PubMed ID: 3691760
[TBL] [Abstract][Full Text] [Related]
22. Induction of lymphokine-activated killer and natural killer cell activities from cryopreserved lymphocytes.
Kawai H; Komiyama A; Katoh M; Yabuhara A; Miyagawa Y; Akabane T
Transfusion; 1988; 28(6):531-5. PubMed ID: 3264091
[TBL] [Abstract][Full Text] [Related]
23. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
24. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
25. Lymphocytes from patients with hairy cell leukaemia enable the distinction of two separate subpopulations of activated lymphocyte killer cells generated in mixed lymphocyte culture.
Werkmeister JA; Boyd AW; Triglia T; Burns GF
Clin Exp Immunol; 1985 Jul; 61(1):103-8. PubMed ID: 2931219
[TBL] [Abstract][Full Text] [Related]
26. Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.
Shimazaki C; Atzpodien J; Wisniewski D; Gulati SC; Kolitz JE; Fried J; Clarkson BD
Acta Haematol; 1988; 80(4):203-9. PubMed ID: 3146198
[TBL] [Abstract][Full Text] [Related]
27. Lysis of leukemia and lymphoma cells by autologous and allogeneic interferon-activated blood mononuclear cells.
Oshimi K; Oshimi Y; Motoji T; Kobayashi S; Mizoguchi H
Blood; 1983 Apr; 61(4):790-8. PubMed ID: 6831042
[TBL] [Abstract][Full Text] [Related]
28. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
Huber C; Aulitzky W; Tilg H; von Lüttichau I; Troppmair J; Nachbauer K; Gastl G
Leukemia; 1987 Apr; 1(4):355-7. PubMed ID: 3669762
[TBL] [Abstract][Full Text] [Related]
29. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors.
Foa R; Fierro MT; Raspadori D; Bonferroni M; Cardona S; Guarini A; Tos AG; di Celle PF; Cesano A; Matera L
Blood; 1990 Oct; 76(7):1349-54. PubMed ID: 2207312
[TBL] [Abstract][Full Text] [Related]
30. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
Atzpodien J; Gulati SC; Shimazaki C; Bührer C; Oz S; Kwon JH; Kolitz JE; Clarkson BD
Oncology; 1988; 45(6):437-43. PubMed ID: 3263598
[TBL] [Abstract][Full Text] [Related]
31. Alpha-interferon activates the natural killer system in patients with hairy cell leukemia.
Semenzato G; Pizzolo G; Agostini C; Ambrosetti A; Zambello R; Trentin L; Luca M; Masciarelli M; Chilosi M; Vinante F
Blood; 1986 Jul; 68(1):293-6. PubMed ID: 3719101
[TBL] [Abstract][Full Text] [Related]
32. An interferon resistant variant of the hairy-cell leukemic cell line, Eskol: biochemical and immunological characterization.
Ozes ON; Klein SB; Reiter Z; Taylor MW
Leuk Res; 1993 Nov; 17(11):983-90. PubMed ID: 7694002
[TBL] [Abstract][Full Text] [Related]
33. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
34. Immunological recovery and dose evaluation in IFN-alpha treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2',5'-oligoadenylate synthetase activity.
Nielsen B; Hokland M; Justesen J; Hasselbalch H; Ellegaard J; Hokland P
Eur J Haematol; 1989 Jan; 42(1):50-9. PubMed ID: 2914594
[TBL] [Abstract][Full Text] [Related]
35. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
36. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
37. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
Pattengale PK; Sundstrom C; Yu AL; Levine A
Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
[TBL] [Abstract][Full Text] [Related]
38. Effects of maximal exercise on natural killer (NK) cell cytotoxicity and responsiveness to interferon-alpha in the young and old.
Woods JA; Evans JK; Wolters BW; Ceddia MA; McAuley E
J Gerontol A Biol Sci Med Sci; 1998 Nov; 53(6):B430-7. PubMed ID: 9823739
[TBL] [Abstract][Full Text] [Related]
39. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
40. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
